Cencora, Inc. (NYSE:COR) Stock Holdings Reduced by Insight Advisors LLC PA

Insight Advisors LLC PA cut its position in shares of Cencora, Inc. (NYSE:COR) by 8.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,371 shares of the company’s stock after selling 134 shares during the period. Insight Advisors LLC PA’s holdings in Cencora were worth $308,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in COR. Czech National Bank raised its position in Cencora by 12.6% during the third quarter. Czech National Bank now owns 35,536 shares of the company’s stock valued at $7,998,000 after acquiring an additional 3,990 shares in the last quarter. Dynamic Advisor Solutions LLC lifted its stake in shares of Cencora by 15.2% in the 3rd quarter. Dynamic Advisor Solutions LLC now owns 1,166 shares of the company’s stock valued at $262,000 after purchasing an additional 154 shares during the last quarter. Tobam boosted its holdings in Cencora by 85.7% in the third quarter. Tobam now owns 25,030 shares of the company’s stock worth $5,634,000 after purchasing an additional 11,549 shares in the last quarter. LVW Advisors LLC boosted its holdings in Cencora by 14.2% in the third quarter. LVW Advisors LLC now owns 3,666 shares of the company’s stock worth $825,000 after purchasing an additional 456 shares in the last quarter. Finally, Iowa State Bank acquired a new position in shares of Cencora during the 3rd quarter valued at about $1,390,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now directly owns 20,329 shares of the company’s stock, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock valued at $17,790,912 over the last 90 days. 10.80% of the stock is owned by company insiders.

Cencora Stock Down 2.8 %

Shares of NYSE:COR opened at $246.11 on Friday. Cencora, Inc. has a 12 month low of $214.77 and a 12 month high of $262.26. The firm has a market cap of $47.57 billion, a P/E ratio of 32.77, a P/E/G ratio of 1.59 and a beta of 0.49. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company’s 50-day moving average price is $239.08 and its two-hundred day moving average price is $236.51.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a net margin of 0.51% and a return on equity of 266.62%. As a group, research analysts forecast that Cencora, Inc. will post 15.32 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.89%. Cencora’s payout ratio is currently 29.29%.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on COR shares. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Wells Fargo & Company lifted their price objective on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a report on Wednesday, January 29th. UBS Group increased their price target on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Barclays increased their price objective on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Finally, Evercore ISI boosted their target price on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Cencora currently has an average rating of “Moderate Buy” and an average target price of $277.90.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.